This is to inform you that pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), the Board of Directors, at ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025. Standalone revenue from operations fell to Rs 2,888.71 lakhs in FY25 from Rs 3,328.93 lakhs in FY24, a decline of about 13%. Profit after tax slipped to Rs 438.28 lakhs (EPS Rs 7.95) from Rs 493.76 lakhs (EPS Rs 8.96). Q4 revenue dropped sharply to Rs 785.16 lakhs versus Rs 1,416.63 lakhs in Q4 FY24. The statutory auditors, Motilal & Associates LLP, issued an unmodified (clean) opinion, though prior periods were audited by the previous firm D M K H & Co. The board also appointed ABHL & Associates as internal auditor for FY26 and D Maurya & Associates as secretarial auditor for five years from FY26.
Shareholders see a year of falling sales and profits with the main Medical segment driving most of the decline, but the company remains profitable with a clean audit report. The mid-year change in statutory auditor (from D M K H & Co to Motilal & Associates LLP) is worth monitoring for any underlying reasons.